Evaluation of blood glucose fluctuation and hypoglycemic effect of dapaglifozin and acarbose in the treatment of type 2 diabetes with CGMS

Evaluation of blood glucose fluctuation and hypoglycemic effect of combination of dapaglifozin and acarbose with mendol 30 in the treatment of type 2 diabetes with CGMS

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800017878

Enrollment

Unknown

Registered

2018-08-19

Start date

2018-08-27

Completion date

Unknown

Last updated

2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

A:dapaglifozin

B:acarbose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with type 2 diabetes with poor blood glucose control with 1 or more oral hypoglycemic drugs (disease duration over 1 year); 2. Aged 18 to 65 years old; 3. Fasting glucose =7, HbA1c=7%; 4. BMI18-35.

Exclusion criteria

Exclusion criteria: Diabetic ketosis, hypertonic status, liver and kidney dysfunction (Cr transaminase exceed 2 times, men more than 1.6 mg/dl, women more than 1.4 mg/dl), instability of cardiovascular system, tumor, trauma, inflammation etc, using insulin sensitization agent, DDP4 inhibitors, GLP1 agonists, acarbose, SGLT2, insulin in recent three months

Design outcomes

Primary

Measure	Time frame
MAGE;CV;total dose of insulin needed;	—

Countries

China

Contacts

Public ContactYawen Bo

The Second Hospital of Changzhou, affiliated to Nanjing Medical University

byw780820@sina.com+86 13915013951

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026